Kodiak DAYBREAK 3期 Zenkuda 和 KSI-501 主要数据预计2026年9月

8-K文件确认，DAYBREAK 3期研究在初治湿性AMD患者中评估Zenkuda和KSI-501，一年主要终点主要数据仍按计划于2026年9月公布。入组已完成，公司继续推进Zenkuda的BLA准备工作。KSI-101在MESI中的第二项3期数据也预计于2026年12月公布。

关键事实

申报时间: 2026年8月13日 20:00
事件: 顶线结果
方向: 中性
公司: KODKodiak Sciences
资产: Zenkuda
来源: SEC 8-K
可信度: 有来源
DRSS 2级改善: 62.5% vs 3.3%（p<0.0001）
STC风险降低: 85%（2.4% vs 15.8%，p=0.0001）

来源摘录

EX-99.1 2 kod-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results PALO ALTO, Calif., August 13, 2026 -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026. "Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach three Phase 3 readouts between now and the end of this year," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "We remain on track for September 2026 DAYBREAK Phase 3 topline results evaluating both Zenkuda and KSI-501 in treatment-naïve wet AMD, followed by December 2026 PEAK Phase 3 Pivotal Analysis 1 topline results evaluating KSI-101 in Macular

SEC 8-K